Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy

被引：0
|
作者：
Huang, Wei [1 ]
Tyburski, Haley [2 ]
Finkelman, Brian [3 ]
Turner, Bradley [3 ]
Weiss, Anna [3 ]
Dhakal, Ajay [4 ]
Skinner, Kristin [3 ]
Hicks, David [3 ]
Zhang, Huina [3 ]
机构：
[1] Penn State Hlth Milton S Hershey Med Ctr, Hershey, PA USA
[2] Univ Rochester, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Rochester, NY USA
[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
146
引用
收藏
页码：S175 / S176
页数：2
相关论文
共 50 条
  • [31] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [32] Activating HER2 mutations in HER2 gene amplification negative breast cancers.
    Bose, R.
    Kavuri, S. M.
    Searleman, A. C.
    Shen, W.
    Shen, D.
    Koboldt, D. C.
    Monsey, J.
    Li, S.
    Ding, L.
    Mardis, E. R.
    Ellis, M. J.
    CANCER RESEARCH, 2012, 72
  • [33] Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
    Valero, Vicente
    Mouabbi, Jason
    Alonzo, Heather
    Pohlmann, Paula
    Lheme, Adaeze
    Hassan, Amy
    Murthy, Rashmi
    Huang, Xuelin
    Qiao, Wei
    Patel, Miral
    Rauch, Gaiane
    Checka, Cristina
    Symmans, W. Fraser
    Hunt, Kelly
    Tripathy, Debu
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [35] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [36] The role of HER2 mutations in resistance to endocrine therapy in ER plus breast cancer
    Nayar, U.
    Cohen, O.
    Oh, C.
    Wagle, N.
    CANCER RESEARCH, 2017, 77
  • [37] Tumor-infiltrating lymphocytes: a prognostic biomarker in neoadjuvant-treated HR positive/HER2 negative breast cancer
    Liu, Yilong
    Zhu, Changyu
    Tong, Rongsheng
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A95 - A96
  • [38] HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different
    Mon, Khin Su
    Zhang, Hui
    Aragao, Alessa
    Tang, Ping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S182 - S183
  • [39] HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
    Mazumder, Aloran
    Shiao, Stephen
    Haricharan, Svasti
    ENDOCRINOLOGY, 2021, 162 (10)
  • [40] Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
    Rodriguez, Mauricio
    Gonzalez, Diego M.
    El-Sharkawy, Farah
    Castano, Mileny
    Madrid, Jorge
    BIOMEDICA, 2023, 43 (03): : 396 - 405
12345